Overexpression of the epidermal growth factor receptor (EGFR) family and its cognate ligand has been correlated with aggressiveness and poor prognosis in various tumours such as breast, ovarian and prostate cancer (Modjtahedi and Dean, 1994; Xie et al, 1995; Turner et al, 1996; Meden and Kuhn, 1997; Chen et al, 2000). This evidence concerns the gene EGFR and Familial prostate cancer.